Pemetrexed in second-line treatment of non-small-cell lung cancer.

Filippo De Marinis, Luigi De Petris

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

According to the updated 2004 guidelines of the American Society of Clinical Oncology (ASCO) on the treatment of advanced non-small-cell lung cancer (NSCLC), docetaxel (Taxotere) can be considered the standard second-line chemotherapy in patients relapsing after frontline therapy. This was based on two phase III trials (TAX 317 and TAX 320) that demonstrated the superiority of docetaxel at 75 mg/m2 in the parameters of survival, quality of life, and disease/symptom control when compared to best supportive care or alternative single-agent chemotherapy. The response rate was approximately 60%, with a median survival time of 7 months and a 1-year survival rate of 30%. Despite the activity demonstrated, this schedule showed an important toxicity profile, with grade 3/4 neutropenia and febrile neutropenia occurring in 70% and 11% of patients, respectively. However, the results obtained by these studies stimulated research interest in new drugs for this disease setting. Pemetrexed (Alimta), a new multitargeted antifolate, has achieved promising results in NSCLC treatment, as a single agent or in combination with other drugs. In the second-line setting, a large phase II study demonstrated good activity of pemetrexed, with an acceptable toxicity profile. This led to a phase III registration trial that compared pemetrexed at 500 mg/m2 to the standard docetaxel dose of 75 mg/m2. While results from this trial demonstrated a similar efficacy of the two regimens in response rate and survival, pemetrexed achieved a better safety profile. These results support the use of pemetrexed as a new option in the second-line treatment of NSCLC.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalOncology
Volume18
Issue number13 Suppl 8
Publication statusPublished - Nov 2004

Fingerprint

Pemetrexed
docetaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Survival Rate
Folic Acid Antagonists
Drug Therapy
Febrile Neutropenia
Survival
Neutropenia
Pharmaceutical Preparations
Appointments and Schedules
Quality of Life
Guidelines
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Pemetrexed in second-line treatment of non-small-cell lung cancer. / De Marinis, Filippo; De Petris, Luigi.

In: Oncology, Vol. 18, No. 13 Suppl 8, 11.2004, p. 38-42.

Research output: Contribution to journalArticle

De Marinis, F & De Petris, L 2004, 'Pemetrexed in second-line treatment of non-small-cell lung cancer.', Oncology, vol. 18, no. 13 Suppl 8, pp. 38-42.
De Marinis, Filippo ; De Petris, Luigi. / Pemetrexed in second-line treatment of non-small-cell lung cancer. In: Oncology. 2004 ; Vol. 18, No. 13 Suppl 8. pp. 38-42.
@article{fb0b200c042f4401ab4a2c0801ddafbf,
title = "Pemetrexed in second-line treatment of non-small-cell lung cancer.",
abstract = "According to the updated 2004 guidelines of the American Society of Clinical Oncology (ASCO) on the treatment of advanced non-small-cell lung cancer (NSCLC), docetaxel (Taxotere) can be considered the standard second-line chemotherapy in patients relapsing after frontline therapy. This was based on two phase III trials (TAX 317 and TAX 320) that demonstrated the superiority of docetaxel at 75 mg/m2 in the parameters of survival, quality of life, and disease/symptom control when compared to best supportive care or alternative single-agent chemotherapy. The response rate was approximately 60{\%}, with a median survival time of 7 months and a 1-year survival rate of 30{\%}. Despite the activity demonstrated, this schedule showed an important toxicity profile, with grade 3/4 neutropenia and febrile neutropenia occurring in 70{\%} and 11{\%} of patients, respectively. However, the results obtained by these studies stimulated research interest in new drugs for this disease setting. Pemetrexed (Alimta), a new multitargeted antifolate, has achieved promising results in NSCLC treatment, as a single agent or in combination with other drugs. In the second-line setting, a large phase II study demonstrated good activity of pemetrexed, with an acceptable toxicity profile. This led to a phase III registration trial that compared pemetrexed at 500 mg/m2 to the standard docetaxel dose of 75 mg/m2. While results from this trial demonstrated a similar efficacy of the two regimens in response rate and survival, pemetrexed achieved a better safety profile. These results support the use of pemetrexed as a new option in the second-line treatment of NSCLC.",
author = "{De Marinis}, Filippo and {De Petris}, Luigi",
year = "2004",
month = "11",
language = "English",
volume = "18",
pages = "38--42",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "13 Suppl 8",

}

TY - JOUR

T1 - Pemetrexed in second-line treatment of non-small-cell lung cancer.

AU - De Marinis, Filippo

AU - De Petris, Luigi

PY - 2004/11

Y1 - 2004/11

N2 - According to the updated 2004 guidelines of the American Society of Clinical Oncology (ASCO) on the treatment of advanced non-small-cell lung cancer (NSCLC), docetaxel (Taxotere) can be considered the standard second-line chemotherapy in patients relapsing after frontline therapy. This was based on two phase III trials (TAX 317 and TAX 320) that demonstrated the superiority of docetaxel at 75 mg/m2 in the parameters of survival, quality of life, and disease/symptom control when compared to best supportive care or alternative single-agent chemotherapy. The response rate was approximately 60%, with a median survival time of 7 months and a 1-year survival rate of 30%. Despite the activity demonstrated, this schedule showed an important toxicity profile, with grade 3/4 neutropenia and febrile neutropenia occurring in 70% and 11% of patients, respectively. However, the results obtained by these studies stimulated research interest in new drugs for this disease setting. Pemetrexed (Alimta), a new multitargeted antifolate, has achieved promising results in NSCLC treatment, as a single agent or in combination with other drugs. In the second-line setting, a large phase II study demonstrated good activity of pemetrexed, with an acceptable toxicity profile. This led to a phase III registration trial that compared pemetrexed at 500 mg/m2 to the standard docetaxel dose of 75 mg/m2. While results from this trial demonstrated a similar efficacy of the two regimens in response rate and survival, pemetrexed achieved a better safety profile. These results support the use of pemetrexed as a new option in the second-line treatment of NSCLC.

AB - According to the updated 2004 guidelines of the American Society of Clinical Oncology (ASCO) on the treatment of advanced non-small-cell lung cancer (NSCLC), docetaxel (Taxotere) can be considered the standard second-line chemotherapy in patients relapsing after frontline therapy. This was based on two phase III trials (TAX 317 and TAX 320) that demonstrated the superiority of docetaxel at 75 mg/m2 in the parameters of survival, quality of life, and disease/symptom control when compared to best supportive care or alternative single-agent chemotherapy. The response rate was approximately 60%, with a median survival time of 7 months and a 1-year survival rate of 30%. Despite the activity demonstrated, this schedule showed an important toxicity profile, with grade 3/4 neutropenia and febrile neutropenia occurring in 70% and 11% of patients, respectively. However, the results obtained by these studies stimulated research interest in new drugs for this disease setting. Pemetrexed (Alimta), a new multitargeted antifolate, has achieved promising results in NSCLC treatment, as a single agent or in combination with other drugs. In the second-line setting, a large phase II study demonstrated good activity of pemetrexed, with an acceptable toxicity profile. This led to a phase III registration trial that compared pemetrexed at 500 mg/m2 to the standard docetaxel dose of 75 mg/m2. While results from this trial demonstrated a similar efficacy of the two regimens in response rate and survival, pemetrexed achieved a better safety profile. These results support the use of pemetrexed as a new option in the second-line treatment of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=13744259507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744259507&partnerID=8YFLogxK

M3 - Article

C2 - 15655935

AN - SCOPUS:13744259507

VL - 18

SP - 38

EP - 42

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 13 Suppl 8

ER -